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Background: Major ABO matching in Hematopoietic stem cell
transplantation (HSCT) is not considered a contraindication to Al-
logeneic HSCT transplantation. Modern reduced intensity condi-
tioning regimens, and reduced toxicity regimens like busulfan and
fludarabine cause much less myeloablation than conventional mye-
loablative regimens like cyclophosphamide with busulfan or TBI.
Therefore recipient cells producing donor red cell specific antibody
are more likely to survive after a major ABO mismatched transplant
and cause red cell aplasia.We hypothesized that there is an increased
incidence of PRCA in Allogeneic HSCT patients who receive re-
duced intensity and reduced toxicity conditioning for stem cell trans-
plantation. The purpose of this study is to estimate the incidence and
describe the natural history of PRCA after HSCT.
Patients andMethods:AllMajor ABOmismatched Allogeneic He-
matopoietic stem cell transplants during a 2-year period (2007-2008)
were prospectively analyzed. PRCA was defined as lack of erythroid
precursors on bone marrow examination 30 days post-transplant,
lack of appearance of donor cells on Forward red cell Typing and be-
ing RBC transfusion dependent.
Results: Between 2007 and 2008, 596 patients underwent reduce in-
tensity Allogeneic HSCT transplants. TheHematopoietic stem cells
wereMajor ABO incompatible in 155(26%). Twelve (7.7%) patients
fulfilled the criteria for PRCA with 6 males/ 6 females and a median
age 51 years (range 24-73). The diagnoses were as follows: AML/
MDS (8), CML/MPD (2), ALL (1), Myeloma (1). The conditioning
regimen was [Fludarabine/Busulfan/ATG (9), Fludarabine/Bulsul-
fan (3), Fludarabine/Melphalan (2) and Fludarabine/Melphalan/
ATG (1). At day 30 chimerism studies showed a median of 90% do-
nor hemopoiesis in T lineage (range 21-100%)and amedian of 100%
(range 99-100%) in myeloid lineage Recovery of erythropoiesis was
noted in 10 patient with a median of 257 days (range 87-364) afterTable 1. Pre-and Post Transplant Data
Pre-Transplant Post-Transplant
Median (Range) Median (Range) Normal Range
Serum Total Bilirubin 0.5 (0.2-1.3) 0.7 (0.1-1.0) 0.0-1.0 mg/dl
Lactate Dehydrogenase 471 (212-2145) 1007 (349-1431) 313-618 IU/L
Alkaline Phosphatase 55 (36-140) 84 (69-238) 38-126 IU/L
Alanine
Aminotransferase
15 (11-54) 26 (12-305) 7-56 IU/L
Hemoglobin 8.4 (7.9-13.7) 11.3 (6.6-13.9) 14.0-18.0 g/dl
Serum Ferritin 1172 (81-3307) 4134 (1437-11634)* 22-322 ng/ml
Liver iron
Concentration
for 6/8 surviving
PRCA patients
15.8 mcg of iron
(12.5- 25 mcg/dry
liver weight)
RBCs Transfused Av 41 (15-131 units)
RBCs Transfusion
Dependence
265 (97-439 days)
Median Follow-up 22 (3-44 months)
*Post-transplant serum ferritin was not obtained on 1 patienttransplant. Four (33%) patients died (1 from disease recurrence
and 3 from transplant related mortality). Two of the patient who
died did not achieve red cell recovery. All the patients had significant
rbc transfusion requirement and developed iron overloadwith signif-
icant elevation of transaminases due to iron deposition in liver.
Conclusion: PRCA frequently (7.7%) occurs with current condi-
tioning regimens necessitating red cell transfusions for manymonths
after transplant resulting in significant iron overload.8
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Reduced intensity conditioning (RIC) regimens have allowed
many patients who would not have tolerated myeloablative condi-
tioning (MAC) to undergo allogeneic hematopoietic stem cell trans-
plantation (HSCT). Even so, dose intensity in RIC regimens vary
andmay affect treatment outcomes. In this analysis, we asked if a dif-
ference in intravenous busulfan dosing (3.2 mg/kg vs. 6.4 mg/kg) in
a fludarabine/busulfan (Flu/Bu) RIC regimen would affect HSCT
outcomes. A total of 188 patients with MDS or AML underwent
Flu/Bu RIC HSCT from matched related (MRD) or matched unre-
lated donors (MUD) at two partner institutions between 2004 and
2008. 118 patients received Bu1 (busulfan 0.8mg/kg/d 4with daily
fludarabine) while 70 patients received Bu2 (busulfan 1.6 mg/kg/d in
divided doses daily  4 with daily fludarabine). Patients had similar
clinical characteristics, including disease risk status, except that pa-
tients receiving Bu1 were younger (median age 58 vs 62, p 5
.0006), received more sirolimus based GVHD prophylaxis regimens
(88% vs 26%, p\ .0001), and had longer follow-up (median, Bu1
39.1months vs Bu2 18.3months, p\ .0001). The choice of RIC reg-
imens was based on institutional standard, enrollment on specific
protocols, and physician preference. The incidence of grades II-IV
acute GVHD (Bu1 19% vs Bu2 17%, p 5 0.82) and chronic
GVHD (2-year cumulative incidence, Bu1 42% vs Bu2 32%, p 5
.07) were similar. Patients who received Bu1 had lower rates of
non-relapse mortality (NRM) at 1-year (Bu1 2% vs Bu2 9%) and
2-years (Bu1 4%vs Bu2 11%, p5 0.013). Cumulative rates of relapse
at 1-year (Bu1 59% vs Bu2 49%) and 2-years (Bu1 68% vs Bu2 49%,
p 5 .022) were significantly higher in patients receiving Bu1.
Table 1. Cumulative Incidences of NRM and Relapse
Bu1 Bu2 p-value1-year NRM 1.7% 8.6%
2-year NRM 3.7% 11.1% 0.013
1-year Relapse 59.3% 48.6%
2-year Relapse 68.1% 48.6% 0.022Progression-free survival at 1-year (Bu1 39% vs Bu2 43%) and 2-
years (Bu1 28% vs Bu2 40%, p 5 .20) was similar between the two
groups. Overall survival at 1-year (Bu1 52% vs Bu2 61%) and 2-years
(Bu1 39% vs Bu2 50%, p 5 .22) was also similar. In patients with
MDS/AML undergoing Flu/Bu RIC SCT, Bu2 appears to have sig-
nificantly lower rates of disease relapse, yet higher rates of NRM.
Longer follow-up is needed to confirm if these differences are dura-
ble and if there are specific risk groups which would benefit more
from the increased intensity of RIC.S153
